As US measles cases rise, biotech firms start developing new treatments
- US measles cases hit a 35-year high amid falling vaccination rates
- No specific treatment exists; care is currently only supportive
- Biotech firms are developing antibody therapies, still years from use
Measles cases in the US have hit a 35-year high as vaccination rates decline, prompting a handful of biotech firms and academic researchers to begin developing treatments for a disease that was previously considered largely conquered through vaccination. There is currently no measles-specific treatment, so doctors can only…